NK012

NK012 is a 'nanodevice' formulation of SN-38 (an irinotecan metabolite). NK012 is an SN-38-releasing polymeric micelle constructed by covalently attaching SN-38 to the block copolymer PEG-PGlu, followed by self-assembly of amphiphilic block copolymers in aqueous media.[1] [2]

It has entered phase II clinical trials for triple-negative breast cancer and relapsed small cell lung cancer.[3]

See also

References

  1. ↑ http://www.cancer.gov/drugdictionary/?CdrID=574615
  2. ↑ Sumitomo; et al. (2008). "Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression".
  3. ↑ http://clinicaltrials.gov/ct2/results?term=NK012


This article is issued from Wikipedia - version of the Thursday, January 07, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.